Researchers from Truveta have found that adoption of adalimumab biosimilars increased substantially following formulary changes in the United States, though more than one in seven patients who ...
Stanford scientists just reported that they've been using AI technology to design the tastiest hamburger. But they did not ...
Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for ...
Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.
20h
Acute respiratory distress syndrome patients improve with experimental monoclonal antibody treatment
Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS. A frequent cause of death during the COVID-19 pandemic, ARDS ...
A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in ...
Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress ...
Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital ...
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
December 31, 2027, led by GoldenTree Asset ManagementFollows recent $165m equity raise strengthening cash positionIncluding equity financing and undrawn loan facility, Alvotech has secured access to ...
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results